Ocular Therapeutix (OCUL) Free Cash Flow (2013 - 2026)

Ocular Therapeutix's Free Cash Flow history runs 14 years deep, the most recent figure standing at -$67.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 44.45% year-over-year to -$67.3 million in Q1 2026; TTM through Mar 2026 was -$237.6 million, a 61.35% decrease from a year earlier, with the FY2025 full-year figure at -$216.9 million, down 60.9% from the prior year.
• Free Cash Flow slipped to -$67.3 million in Q1 2026 per OCUL's latest filing, from -$57.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.6 million in Q3 2023 and bottomed at -$67.3 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$28.3 million (2023), against an average of -$32.7 million.
• Across the five-year window, Free Cash Flow surged 80.37% in 2023 and plunged 1291.33% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$17.9 million in 2022, then sank by 58.26% to -$28.3 million in 2023, then sank by 39.61% to -$39.5 million in 2024, then sank by 44.62% to -$57.1 million in 2025, then dropped by 17.92% to -$67.3 million in 2026.
• Per Business Quant, the three latest OCUL Free Cash Flow figures stand at -$67.3 million (Q1 2026), -$57.1 million (Q4 2025), and -$56.7 million (Q3 2025).